NO20014488L - Amidderivater - Google Patents

Amidderivater

Info

Publication number
NO20014488L
NO20014488L NO20014488A NO20014488A NO20014488L NO 20014488 L NO20014488 L NO 20014488L NO 20014488 A NO20014488 A NO 20014488A NO 20014488 A NO20014488 A NO 20014488A NO 20014488 L NO20014488 L NO 20014488L
Authority
NO
Norway
Prior art keywords
halogeno
aryl
group
amide derivatives
arylamino
Prior art date
Application number
NO20014488A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014488D0 (no
Inventor
Dearg Sutherland Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906277.0A external-priority patent/GB9906277D0/en
Priority claimed from GB0002472A external-priority patent/GB0002472D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20014488D0 publication Critical patent/NO20014488D0/no
Publication of NO20014488L publication Critical patent/NO20014488L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
NO20014488A 1999-03-17 2001-09-14 Amidderivater NO20014488L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9906277.0A GB9906277D0 (en) 1999-03-17 1999-03-17 Amide derivatives
GB0002472A GB0002472D0 (en) 2000-02-03 2000-02-03 Amide derivatives
PCT/GB2000/000914 WO2000055120A1 (en) 1999-03-17 2000-03-13 Amide derivatives

Publications (2)

Publication Number Publication Date
NO20014488D0 NO20014488D0 (no) 2001-09-14
NO20014488L true NO20014488L (no) 2001-11-14

Family

ID=26243557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014488A NO20014488L (no) 1999-03-17 2001-09-14 Amidderivater

Country Status (22)

Country Link
US (2) US6548514B1 (de)
EP (1) EP1163212B1 (de)
JP (1) JP2002539187A (de)
KR (1) KR20010110668A (de)
CN (1) CN100352804C (de)
AT (1) ATE303357T1 (de)
AU (1) AU761291B2 (de)
BR (1) BR0009041A (de)
CA (1) CA2361819A1 (de)
CZ (1) CZ20013276A3 (de)
DE (1) DE60022328T2 (de)
DK (1) DK1163212T3 (de)
ES (1) ES2246830T3 (de)
HU (1) HUP0105136A3 (de)
IL (1) IL145277A0 (de)
NO (1) NO20014488L (de)
NZ (1) NZ513726A (de)
PL (1) PL350448A1 (de)
RU (1) RU2284187C2 (de)
SK (1) SK13132001A3 (de)
TR (1) TR200102568T2 (de)
WO (1) WO2000055120A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
DK1017378T3 (da) 1997-09-23 2003-03-17 Astrazeneca Ab Amidderivater til behandling af sygdomme medieret af cytokiner
SK286247B6 (sk) 1998-05-15 2008-06-06 Astrazeneca Ab Benzamidové deriváty, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú a ich použitie pri príprave liečiva na liečbu chorobných stavov sprostredkovaných cytokínmi
PL195600B1 (pl) 1998-05-15 2007-10-31 Astrazeneca Ab Pochodne benzamidowe, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie do wytwarzania leku do leczenia stanów medycznych powstających za pośrednictwem cytokin
WO2000007991A1 (en) 1998-08-04 2000-02-17 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
ATE254105T1 (de) 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
AU761453B2 (en) * 1999-03-17 2003-06-05 Astrazeneca Ab Amide derivatives
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
KR100407640B1 (ko) * 2000-12-19 2003-12-01 주식회사 태평양 신규한 디페닐 아미드 유도체, 그의 제조방법 및 이를포함하는 약학 및 화장료 조성물
JP2002338537A (ja) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
AU2002350172A1 (en) * 2001-12-07 2003-06-23 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
CA2533900A1 (en) * 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
BR122015015718B1 (pt) 2004-01-28 2016-05-10 Mitsui Chemicals Inc derivados de amida
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
DE102005023834A1 (de) * 2004-11-20 2006-05-24 Bayer Healthcare Ag Substituierte[(Phenylethanoyl)amino]benzamide
WO2006067445A2 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
CN101128454A (zh) * 2004-12-22 2008-02-20 阿斯利康(瑞典)有限公司 用作抗癌药物的吡啶羧酰胺衍生物
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US7759337B2 (en) * 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
EP1879884B1 (de) * 2005-05-03 2010-08-25 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren auf azolbasis
MX295245B (es) * 2005-06-21 2012-01-26 Mitsui Chemicals Inc Derivado de amida e insecticida que contiene el mismo.
WO2006137395A1 (ja) * 2005-06-23 2006-12-28 Mitsui Chemicals, Inc. アミド誘導体、該化合物を含有する殺虫剤およびその使用方法
EP1741811B1 (de) * 2005-07-07 2007-08-22 Rohm and Haas Company Faser mit antimikrobiell wirksamer Zusammensetzung
JP4580836B2 (ja) * 2005-07-25 2010-11-17 三井化学アグロ株式会社 殺虫殺菌組成物
CA2616749C (en) * 2005-07-27 2012-01-03 Mitsui Chemicals, Inc. Composition for preventing harmful organisms
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2007124181A2 (en) * 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2008011032A1 (en) * 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
US8101612B2 (en) * 2006-09-05 2012-01-24 Amgen Inc. Phthalazine compounds and methods of use
WO2008031534A1 (en) 2006-09-11 2008-03-20 Syngenta Participations Ag Insecticidal compounds
WO2008045393A2 (en) * 2006-10-11 2008-04-17 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
EP2083816A2 (de) 2006-10-27 2009-08-05 Brystol-Myers Squibb Company Heterocyclische amidverbindungen als kinasehemmer
WO2008136948A1 (en) 2007-05-07 2008-11-13 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
WO2009038784A1 (en) * 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
EP2334673A1 (de) 2008-08-29 2011-06-22 Amgen Inc. Pyrido[3,2-d]pyridazin-2-(1h)-onverbindungen als p38-modulatoren und verfahren zu deren anwendung
US8455495B2 (en) 2008-08-29 2013-06-04 Amgen Inc. Pyridazino-pyridinone compounds and methods of use
US8772481B2 (en) 2008-10-10 2014-07-08 Amgen Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
GB0902648D0 (en) * 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP2016519674A (ja) 2013-03-20 2016-07-07 バイエル・ファルマ・アクティエンゲゼルシャフト 過剰増殖障害を治療または予防するための３−アセチルアミノ−１−（フェニル−ヘテロアリール−アミノカルボニルまたはフェニル−ヘテロアリール−カルボニルアミノ）ベンゼン誘導体
JP2016521259A (ja) 2013-03-20 2016-07-21 バイエル・ファルマ・アクティエンゲゼルシャフト 置換Ｎ−ビフェニル−３−アセチルアミノ−ベンズアミドおよびＮ−［３−（アセチルアミノ）フェニル］−ビフェニル−カルボキサミドならびにＷｎｔシグナル伝達経路の阻害剤としてのそれらの使用
ME03398B (de) * 2013-12-17 2020-01-20 Lilly Co Eli Dimethylbenzoesäureverbindungen
MX2016012175A (es) * 2014-03-20 2017-01-19 Bayer Pharma AG Nuevos compuestos.
AP2016009433A0 (en) * 2014-03-20 2016-09-30 Bayer Pharma AG Inhibitors of the wnt signalling pathways
US9688637B2 (en) 2014-08-21 2017-06-27 Northwestern Universtiy 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members
CA2976973A1 (en) 2015-02-20 2016-08-25 Bayer Pharma Aktiengesellschaft N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathways
JP2018513112A (ja) 2015-02-20 2018-05-24 バイエル・ファルマ・アクティエンゲゼルシャフト Ｗｎｔシグナル伝達経路の阻害剤としての３−カルバモイルフェニル−４−カルボキサミドおよびイソフタルアミド誘導体
CN107250120A (zh) 2015-02-20 2017-10-13 拜耳制药股份公司 作为Wnt信号通路抑制剂的1,3,4‑噻二唑‑2‑基‑苯甲酰胺衍生物
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN108713019B (zh) 2016-03-17 2021-06-15 豪夫迈·罗氏有限公司 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE522788C (de) * 1928-11-01 1931-04-15 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Carbonsaeurearyliden der Benzolreihe
NL129433C (de) * 1963-09-21
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
CA2020887A1 (en) * 1989-07-28 1991-01-29 Michael Klaus Aromatic carboxylic amides
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
EP0849256B1 (de) * 1995-08-22 2005-06-08 Japan Tobacco Inc. Amid-verbindungen und ihre anwendung
JPH09124571A (ja) * 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
DK1017378T3 (da) * 1997-09-23 2003-03-17 Astrazeneca Ab Amidderivater til behandling af sygdomme medieret af cytokiner
SK286247B6 (sk) * 1998-05-15 2008-06-06 Astrazeneca Ab Benzamidové deriváty, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú a ich použitie pri príprave liečiva na liečbu chorobných stavov sprostredkovaných cytokínmi
PL195600B1 (pl) 1998-05-15 2007-10-31 Astrazeneca Ab Pochodne benzamidowe, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie do wytwarzania leku do leczenia stanów medycznych powstających za pośrednictwem cytokin
WO2000007991A1 (en) 1998-08-04 2000-02-17 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
ATE254105T1 (de) * 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
ATE232205T1 (de) 1998-10-01 2003-02-15 Astrazeneca Ab Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
AU761453B2 (en) 1999-03-17 2003-06-05 Astrazeneca Ab Amide derivatives
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives

Also Published As

Publication number Publication date
DE60022328T2 (de) 2006-06-01
NZ513726A (en) 2001-09-28
BR0009041A (pt) 2001-12-26
HK1041875A1 (en) 2002-07-26
AU761291B2 (en) 2003-05-29
CN100352804C (zh) 2007-12-05
JP2002539187A (ja) 2002-11-19
KR20010110668A (ko) 2001-12-13
HUP0105136A3 (en) 2002-05-28
US6548514B1 (en) 2003-04-15
TR200102568T2 (tr) 2002-05-21
US20030186966A1 (en) 2003-10-02
CZ20013276A3 (cs) 2001-12-12
CN1344249A (zh) 2002-04-10
WO2000055120A1 (en) 2000-09-21
RU2284187C2 (ru) 2006-09-27
SK13132001A3 (sk) 2002-02-05
US6794380B2 (en) 2004-09-21
IL145277A0 (en) 2002-06-30
PL350448A1 (en) 2002-12-16
HUP0105136A2 (hu) 2002-04-29
RU2001128067A (ru) 2004-01-20
ES2246830T3 (es) 2006-03-01
EP1163212B1 (de) 2005-08-31
EP1163212A1 (de) 2001-12-19
DK1163212T3 (da) 2005-11-14
ATE303357T1 (de) 2005-09-15
CA2361819A1 (en) 2000-09-21
AU3178000A (en) 2000-10-04
NO20014488D0 (no) 2001-09-14
DE60022328D1 (de) 2005-10-06

Similar Documents

Publication Publication Date Title
ATE303357T1 (de) Amid-derivate
MY128501A (en) Amide derivatives
ATE286501T1 (de) Pyrimidinderivate
HUT60250A (en) Process for producing new phenylimidazolidines, their thione and iminoderivatives, and pharmaceutical compositions comprising same as active ingredient
NZ509318A (en) Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines
DK1117653T3 (da) Quinolin- og quinazolinderivater og deres anvendelse som inhibitorer af cykokin-merierede sygdomme
MY142177A (en) Benzamide derivatives useful as histone deacetylase inhibitors
GB0206860D0 (en) Compounds
PL346854A1 (en) Benzamide derivatives and their use as cytokine inhibitors
ATE355064T1 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
DK1165566T3 (da) Pyridin- og pyrimidinderivater og deres anvendelse som inhibitorer af cytokin-medieret sygdom
DK1441735T3 (da) N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integrase
DE60014393D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
ATE375984T1 (de) Chinazolin derivate
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
IL131216A0 (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
TH22511A (th) Use of quinoxalines in combination with protease inhibitors as medicaments for treation, aids and/or hiv infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application